<?xml version="1.0" encoding="UTF-8"?>
<ref id="B214-viruses-12-00376">
 <label>214.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Davidson</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>McCabe</surname>
    <given-names>T.M.</given-names>
   </name>
   <name>
    <surname>Crotta</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Gad</surname>
    <given-names>H.H.</given-names>
   </name>
   <name>
    <surname>Hessel</surname>
    <given-names>E.M.</given-names>
   </name>
   <name>
    <surname>Beinke</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Rune</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Andreas</surname>
    <given-names>W.</given-names>
   </name>
  </person-group>
  <article-title>IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment</article-title>
  <source>EMBO Mol. Med.</source>
  <year>2016</year>
  <volume>8</volume>
  <fpage>1099</fpage>
  <lpage>1112</lpage>
  <pub-id pub-id-type="doi">10.15252/emmm.201606413</pub-id>
  <?supplied-pmid 27520969?>
  <pub-id pub-id-type="pmid">27520969</pub-id>
 </element-citation>
</ref>
